Company Monitoring Page for Incyte

latest headlines for company on cafepharma

Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Endpoints
Thu, 07/23/20 - 11:06 am
Tags:
ruxolitinib, Novartis, Incyte, graft vs host disease
Why Incyte's Q1 Loss Isn't As Bad As It Looks
Motley Fool
Tue, 05/5/20 - 11:52 pm
Tags:
Incyte, earnings
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Endpoints
Mon, 04/27/20 - 09:43 am
Tags:
Novartis, Incyte, AACR, lung cancer, MET inhibitors, capmatinib
Novartis, Incyte's Jakafi boosts its case in graft-versus-host disease with another phase 3 win
Fierce Pharma
Wed, 04/22/20 - 10:45 pm
Tags:
Novartis, Incyte, Jakafi, clinical trials, COVID-19, cytokine storm, graft vs host disease
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Endpoints
Mon, 04/20/20 - 10:58 am
Tags:
Incyte, Pemazyre, pemigatinib, bile duct cancer, cholangiocarcinoma, FDA
Incyte, Novartis launch drug study to treat coronavirus complication
Marketwatch
Sat, 04/18/20 - 11:22 pm
Tags:
Incyte, Novartis, cytokine storm, COVID-19, clinical trials, Jakafi
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Motley Fool
Fri, 04/3/20 - 12:02 am
Tags:
cancer, COVID-19, Incyte, Jakafi
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Pharmaceutical Business Review
Tue, 03/17/20 - 11:59 am
Tags:
Eli Lilly, Incyte, breakthrough therapy, FDA, baricitinib, alopecia areata
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Fierce Biotech
Wed, 02/19/20 - 09:58 am
Tags:
Incyte, ruxolitinib, clinical trials, atopic dermatitis
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Fierce Pharma
Thu, 02/13/20 - 11:28 pm
Tags:
Incyte, Jakafi, pemigatinib
Incyte Earnings, Revenue Beat in Q4
Yahoo/Investing.com
Thu, 02/13/20 - 11:00 am
Tags:
Incyte, earnings
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Motley Fool
Thu, 02/13/20 - 12:12 am
Tags:
Eli Lilly, Incyte, olumiant, eczema, clinical trials, atopic dermatitis
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Tue, 02/11/20 - 10:28 am
Tags:
Incyte, Novartis, FDA, capmatinib, prioirty review, non-small cell lung cancer
Incyte's skin disease drug meets main goal in late-stage study
Yahoo/Reuters
Tue, 01/28/20 - 12:00 pm
Tags:
Incyte, clinical trials, atopic dermatitis, ruxolitinib
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Tags:
Incyte, MorphoSys, lymphoma, tafasitamab
Incyte stock slammed after study fails to hit goal
Marketwatch
Thu, 01/2/20 - 11:44 pm
Tags:
Incyte, clinical trials, itacitinib, graft vs host disease
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Investors Business Daily
Tue, 12/3/19 - 09:47 am
Tags:
Incyte, Jakafi, innovation
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
Fri, 11/29/19 - 02:24 pm
Tags:
FDA, Incyte, priority review, pemigatinib, cholangiocarcinoma
Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J
BioSpace
Sat, 11/2/19 - 07:55 pm
Tags:
earnings, Pfizer, Merck, Amgen, Incyte, JNJ
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Yahoo/Zacks.com
Sat, 10/19/19 - 01:28 pm
Tags:
Incyte, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.